Estradiol/nomegestrol sequential

Drug Profile

Estradiol/nomegestrol sequential

Alternative Names: E2/Nomac sequential; EMM 210066; Naemis; Nomac/E2 sequential; TX 45066

Latest Information Update: 08 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Theramex SAM
  • Developer Theramex
  • Class Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Pregnadienes; Progesterone congeners; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Menopausal syndrome

Most Recent Events

  • 01 Feb 2018 Teva Women's Health was sold by Teva Pharmaceuticals to CVC Capital Partners, to create an international pharmaceutical company dedicated to Women’s Health named Theramex
  • 06 Jan 2011 Theramex SAM has been acquired by Teva Pharmaceutical Industries
  • 31 Dec 2003 Launched for Menopausal syndrome in Europe (PO) - First global launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top